Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists

Rezaei, Shawheen J.; Vogel, Andre C.; Gazdag, Brittany; Alakel, Nicholas; Kumar, Aditya; Mateen, Farrah J.

doi:10.1016/j.jneuroim.2020.577320

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, 74% of neurologists differed in the dose for RTX, and 90% of neurologists changed the dosing interval for RTX. 86 Although INEB has not been reported to increase the risk of COVID-19, 87 the risk of COVID-19 could be inferred from its similar mechanism of action to other B-cell-depleting agents, such as RTX and OCR.…”

Section: Progressive Multifocal Leukoencephalopathymentioning

confidence: 99%

“…Interestingly, a survey of 192 neurologists who saw patients with NMO from the USA and Canada found that 52% of these patients had been treated with RTX and 11% with eculizumab (ECZ) before the COVID‐19 pandemic. Among them, 74% of neurologists differed in the dose for RTX, and 90% of neurologists changed the dosing interval for RTX 86 . Although INEB has not been reported to increase the risk of COVID‐19, 87 the risk of COVID‐19 could be inferred from its similar mechanism of action to other B‐cell‐depleting agents, such as RTX and OCR.…”

Section: Viral Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Infectious issues of therapeutic monoclonal antibodies in multiple sclerosis and neuromyelitis optica spectrum disorders

Tagawa

2022

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Various effective monoclonal antibodies (mAbs) have been approved for both multiple sclerosis (MS) and anti-aquaporin-4-seropositive neuromyelitis optica spectrum disorders worldwide, including in Japan. As these newer mAbs have distinct modes of action that effectively suppress the recurrence of inflammation and slow disability progression, they can modulate and interfere with the protective immune response against pathogens, resulting in various infectious complications. Among various mAbs, natalizumab (NTZ) has the highest risk of causing progressive multifocal leukoencephalopathy (PML), a rare but fatal opportunistic brain infection caused by John Cunningham polyomavirus. Switching from NTZ to B-cell-depleting mAbs, such as ocrelizumab, is also a possible risk factor for PML development. Alemtuzumab carries the risk of reactivation of varicella-zoster virus (VZV); therefore, prophylactic acyclovir treatment is required. NTZ has also been associated with VZV reactivation.Eculizumab can cause severe meningococcal infection due to Neisseria meningitis, and vaccination prior to treatment induction is required. Attention to the reactivation of hepatitis B or Mycobacterium tuberculosis is also needed during mAb therapy. Additionally, in the era of severe acute respiratory syndrome coronavirus 2 infection (COVID-19), the risk for of developing severe COVID-19 may be associated with some mAbs, such as B-cell-depleting agents. Thorough understanding and mitigation strategies for infectious risks are essential.

show abstract

Section: Progressive Multifocal Leukoencephalopathymentioning

confidence: 99%

Section: Viral Infectionsmentioning

confidence: 99%

Infectious issues of therapeutic monoclonal antibodies in multiple sclerosis and neuromyelitis optica spectrum disorders

Tagawa

2022

Clinical & Exp Neuroim

View full text Add to dashboard Cite

show abstract

“…It is possible that eculizumab renders people susceptible to SARS-CoV-2 infection; however, a protective effect against the development of severe COVID-19 disease may also occur [ 7 – 9 ]. Although eculizumab has been given safely during COVID-19, a survey of 192 neurologists from the United States and Canada in April 2020 found that many felt eculizumab could put their patients at risk for COVID-19 [ 10 ].…”

mentioning

confidence: 99%